Evaluating Biomarkers of Neuronal Degeneration and Neuroinflammation in CSF of Patients With Multiple Sclerosis–osteopontin as a Potential Marker of Clinical Severity

Journal of the Neurological Sciences - Netherlands
doi 10.1016/j.jns.2013.04.024
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Elsevier BV

Related search

Biomarkers of Inflammation and Axonal Degeneration/Damage in Patients With Newly Diagnosed Multiple Sclerosis: Contributions of the Soluble CD163 CSF/Serum Ratio to a Biomarker Panel

PLoS ONE
Multidisciplinary
2015English

Neuroinflammation in Neuronal Degeneration and Repair

Cell Death and Differentiation
Cell BiologyMolecular Biology
2007English

Circulating Osteopontin: A Dual Marker of Bone Destruction and Angiogenesis in Patients With Multiple Myeloma

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2011English

Soluble CD163 as a Marker of Macrophage Activity in Newly Diagnosed Patients With Multiple Sclerosis

PLoS ONE
Multidisciplinary
2014English

CSF Β-Amyloid Predicts Prognosis in Patients With Multiple Sclerosis

Multiple Sclerosis
Neurology
2018English

Diffusion Tensor-Mri Evidence for Extra-Axonal Neuronal Degeneration in Caudate and Thalamic Nuclei of Patients With Multiple Sclerosis

American Journal of Neuroradiology
MedicineNuclear MedicineNeurologyImagingRadiology
2012English

Ultrasound Detection of Knee Joint Degeneration in Patients With Multiple Sclerosis

Journal of Rehabilitation Medicine
MedicinePhysical TherapySports TherapyRehabilitationSports Science
2016English

KIR4.1 Antibodies as Biomarkers in Multiple Sclerosis

Frontiers in Neurology
Neurology
2014English

Polymorphism of the Osteopontin Gene and Clinical Course of Multiple Sclerosis in the Polish Population

Folia Neuropathologica
Forensic MedicinePathologyNeurology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy